Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. (2021)
Attributed to:
The impact of IFTIM3 genetic variation on Influenza virus infection, immune responses and disease outcome
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41591-020-01179-4
PubMed Identifier: 33335322
Publication URI: http://europepmc.org/abstract/MED/33335322
Type: Journal Article/Review
Volume: 27
Parent Publication: Nature medicine
Issue: 2
ISSN: 1078-8956